This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes the:
- A decision made by a delegate of the Secretary pursuant to regulations 42ZCZR and 42ZCZU;
- reasons for that final decision; and
- date of effect of the decision.
Final decision and reasons
We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au.
Contents
- 1 Notice of final decisions to amend (or not amend) the current Poisons Standard
- 2 Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #40, November 2022)
- 2.1 Final decision in relation to paracetamol
- 2.2 Final decision in relation to ivermectin
- 2.3 Final decision in relation to brimonidine
- 2.4 Final decision in relation to fexofenadine
- 2.5 Final decision in relation to ibuprofen
- 2.6 Final decision in relation to melatonin
- 3 Final decisions on proposed amendments referred to the Advisory Committee on Medicines and Chemicals Scheduling (ACMS-ACCS #32, November 2022)
- 4 Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #35, November 2022)
- 4.1 Final decision in relation to ethalfluralin
- 4.2 Final decision in relation to tigolaner
- 5 Amendments to the Poisons Standard made as delegate-only decisions
- 5.1 Final decision in relation to spiromesifen
- 6 Amendments to the Poison Standard in relation to New Chemical Entities (NCEs)
- 6.1 Andexanet alfa
- 6.2 Avatrombopag
- 6.3 Difelikefalin
- 6.4 Ivosidenib
- 6.5 Pralsetinib